Crinetics gets FDA rare pediatric disease designation for congenital hyperinsulinism

Crinetics Logo

The FDA granted Crinetics Pharmaceuticals’ (NASDAQ:CRNX) CRN04777 rare pediatric disease designation for the treatment of congenital hyperinsulinism.

Congenital hyperinsulinism occurs when infants are born with life-threatening hypoglycemia due to excess insulin secretion. 

“Failure to recognize and effectively treat this disease can lead to seizures, permanent neurological sequelae, and even death,” Dr. Christine Ferrara-Cook, Crinetics’ medical director, said in a statement.

“CRN04777 is the first oral, selective nonpeptide somatostatin receptor type 5 receptor agonist designed to reduce insulin secretion and is intended to be a universal treatment for all patients with congenital hyperinsulinism,” she added.

Crinetics plans to launch a Phase 1 study of CRN04777 for the treatment of congenital hyperinsulinism in early 2021.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.